Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis.

Kim Hørslev-Petersen; Merete Lund Hetland; P. Junker; Jan Pødenphanth; Torkell Ellingsen; P. Ahlqvist; Hanne Merete Lindegaard; A. Linauskas; Annette Schlemmer; M.Y. Dam; I. Hansen; Tine Lottenburger; A. Jørgensen; Sophine Boysen Krintel; J. Raun; C.G. Ammitzbøll; Julia S. Johansen; Mikkel Østergaard; K. Steengaard-Pedersen

Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis.

Kim Hørslev-Petersen, Merete Lund Hetland, P. Junker, Jan Pødenphanth, Torkell Ellingsen, P. Ahlqvist, Hanne Merete Lindegaard, A. Linauskas, Annette Schlemmer, M.Y. Dam, I. Hansen, Tine Lottenburger, A. Jørgensen, Sophine Boysen Krintel, J. Raun, C.G. Ammitzbøll, Julia S. Johansen, Mikkel Østergaard, K. Steengaard-Pedersen

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	72
Udgave nummer	Suppl. 3
Sider (fra-til)	236
Antal sider	1
ISSN	0003-4967
Status	Udgivet - 2013

Citationsformater

Hørslev-Petersen, K., Hetland, M. L., Junker, P., Pødenphanth, J., Ellingsen, T., Ahlqvist, P., Lindegaard, H. M., Linauskas, A., Schlemmer, A., Dam, M. Y., Hansen, I., Lottenburger, T., Jørgensen, A., Krintel, S. B., Raun, J., Ammitzbøll, C. G., Johansen, J. S., Østergaard, M., & Steengaard-Pedersen, K. (2013). Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis. Annals of the Rheumatic Diseases, 72(Suppl. 3), 236.

Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis. / Hørslev-Petersen, Kim; Hetland, Merete Lund; Junker, P. et al.
I: Annals of the Rheumatic Diseases, Bind 72, Nr. Suppl. 3, 2013, s. 236.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Hørslev-Petersen, K, Hetland, ML, Junker, P, Pødenphanth, J, Ellingsen, T, Ahlqvist, P, Lindegaard, HM, Linauskas, A, Schlemmer, A, Dam, MY, Hansen, I, Lottenburger, T, Jørgensen, A, Krintel, SB, Raun, J, Ammitzbøll, CG, Johansen, JS , Østergaard, M & Steengaard-Pedersen, K 2013, 'Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis.', Annals of the Rheumatic Diseases, bind 72, nr. Suppl. 3, s. 236.

Hørslev-Petersen K, Hetland ML, Junker P, Pødenphanth J, Ellingsen T, Ahlqvist P et al. Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis. Annals of the Rheumatic Diseases. 2013;72(Suppl. 3):236.

Hørslev-Petersen, Kim ; Hetland, Merete Lund ; Junker, P. et al. / Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis. I: Annals of the Rheumatic Diseases. 2013 ; Bind 72, Nr. Suppl. 3. s. 236.

@article{3e43cec7820a4e85b4f161b4eee16926,

title = "Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis.",

author = "Kim H{\o}rslev-Petersen and Hetland, {Merete Lund} and P. Junker and Jan P{\o}denphanth and Torkell Ellingsen and P. Ahlqvist and Lindegaard, {Hanne Merete} and A. Linauskas and Annette Schlemmer and M.Y. Dam and I. Hansen and Tine Lottenburger and A. J{\o}rgensen and Krintel, {Sophine Boysen} and J. Raun and C.G. Ammitzb{\o}ll and Johansen, {Julia S.} and Mikkel {\O}stergaard and K. Steengaard-Pedersen",

year = "2013",

language = "English",

volume = "72",

pages = "236",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "Suppl. 3",

}

TY - ABST

T1 - Improved remission rates acquired by adding adalimumab to methotrexate and intraarticular glucocorticoid cannot be maintained after withdrawal of adalimumab. A 2-year investigator initiated randomized, controlled study on early rheumatoid arthritis.

AU - Hørslev-Petersen, Kim

AU - Hetland, Merete Lund

AU - Junker, P.

AU - Pødenphanth, Jan

AU - Ellingsen, Torkell

AU - Ahlqvist, P.

AU - Lindegaard, Hanne Merete

AU - Linauskas, A.

AU - Schlemmer, Annette

AU - Dam, M.Y.

AU - Hansen, I.

AU - Lottenburger, Tine

AU - Jørgensen, A.

AU - Krintel, Sophine Boysen

AU - Raun, J.

AU - Ammitzbøll, C.G.

AU - Johansen, Julia S.

AU - Østergaard, Mikkel

AU - Steengaard-Pedersen, K.

PY - 2013

Y1 - 2013

M3 - Conference abstract in journal

SN - 0003-4967

VL - 72

SP - 236

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl. 3

ER -